What are the oncologic outcomes for myxoinflammatory fibroblastic sarcomas? - Outcome oncologico del sarcoma mixoinfiammatorio fibroblastico

Title

Code

OS-MIFS

Type

Osservazionale

Start Year

2024

Status

Terminato

Principal Investigator

051-6366012 (segreteria)

davidemaria.donati@ior.it

Donati Davide Maria, MD

Director

3rd Orthopaedic and Traumatologic Clinic prevalently Oncologic

Operational unit that carry out the study

complex unit

Clinica Ortopedica e Traumatologica III a prevalente indirizzo Oncologico

Director

Donati Davide Maria, MD

Go to the details >>

Description

Studio clinico promosso da University of Toronto Mount Sinai Hospital Canada

Documents and Videos attachament

Attachment

Nulla osta allo studio clinico prot. OS-MIFS

Wednesday 7 January 2026, 16:25

PG0015146_2024_Nulla osta DG_OS-MIFS - Donati.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

What are the oncologic outcomes for myxoinflammatory fibroblastic sarcomas? - Outcome oncologico del sarcoma mixoinfiammatorio fibroblastico

Principal Investigator

Operational unit that carry out the study

Description

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

What are the oncologic outcomes for myxoinflammatory fibroblastic sarcomas? - Outcome oncologico del sarcoma mixoinfiammatorio fibroblastico

Principal Investigator

Operational unit that carry out the study

Description

Documents and Videos attachament

You might also be interested in